Business
Summit Therapeutics Adds Lunit AI Pathology to Ivonescimab Research
The Miami-based biopharma will use Lunit SCOPE IO to analyze standard tissue slides for biomarker and patient-selection work tied to its PD-1/VEGF bispecific antibody.
Summit Therapeutics Inc.